MIAMI and LJUBLJANA, Slovenia, Jan. 27 /PRNewswire/ -- Fuisz Pharma today announced the development of a novel anti-abuse system intended for use with abuse prone drugs. This system seeks to address the misuse of addictive drugs with a particular emphasis on opiates and is applicable to all dosage forms.
Fuisz Pharma President, Joseph Matus Fuisz commented: "The desirability of an effective anti abuse system is well understood. The United States Government has estimated that thirty six million Americans will abuse a medication at some point in their lifetime. Abuse is particularly prevalent in the pain area. Notwithstanding this need, the industry has found it challenging to implement abuse resistant dosage forms despite Herculean formulation efforts. This is due primarily to the fundamental tension between the bioavailability of a drug in the body and the prevention of extraction from the dosage form and other types of misuse by a highly motivated and sophisticated population of abusers."
Mr. Fuisz continued: "The Fuisz system for preventing abuse combines, as the best inventions do, novelty with simplicity. We are confident that our anti-abuse system will be welcomed by our pharmaceutical partners as well as by those concerned with drug misuse issues and the public and private health practitioner."
Noted pharmaceutical inventor Richard C. Fuisz, M.D. (http://en.wikipedia.org/wiki/Richard_Carl_Fuisz) was one of the inventors of the methodology.
Fuisz Pharma is a private pharmaceutical company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery (orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, etc.) and have extensive experience working with big and specialty pharma. Fuisz Pharma has offices in Miami and Los Angeles as well as a presence in the EU through Ljubljana, Slovenia.
SOURCE Fuisz Pharma
|SOURCE Fuisz Pharma|
Copyright©2010 PR Newswire.
All rights reserved